Dbv Technologies (DBV) | Stock Overview & Key Data
Dbv Technologies S.A. | Mid-cap | Healthcare
Dbv Technologies S.A. | Mid-cap | Healthcare
Dbv Technologies Performance Comparison
Stock Range
Today's Range
Low: €1.72
High: €1.87
on August 8, 2025
52 Week Range
Low: €0.51
High: €2.38
on November 21, 2024
on May 14, 2025
All-Time High: €86.64 on October 9, 2017
Explore how other French stocks compare to their 52-week ranges: View FR Market 52-Week Insights
Key Statistics
Market Cap
€233.4M
EPS
-0.97
P/E Ratio (TTM)
-1.48
Forward P/E
-2.37
P/B Ratio
2.71
PEG Ratio
-2.37
Div. Yield
N/A
ROE
-148.09%
Beta
0.331
Debt to Equity
8.92
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-2,806.14%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-59.16%
Return on Equity (TTM)
-148.09%
EBITDA
€0
Net Income (TTM)
€-105.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.03
Quarterly Revenue Growth (YoY)
26.20%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Dbv Technologies DBV | 233.40M Mid-cap | 4.22% | -5.98% | 3.59% | 116.25% | 170.31% | 105.95% | -65.33% | -57.60% |
| Abivax SA ABVX | 4.49B Large-cap | -5.31% | 791.18% | 913.38% | 961.30% | 732.42% | 474.95% | 572.59% | 214.97% |
| Valneva SE VLA | 546.93M Mid-cap | 9.79% | 50.21% | 22.53% | 14.70% | 55.41% | 11.58% | -65.68% | -34.65% |
| Medincell S.A MEDCL | 524.62M Mid-cap | -6.41% | -1.79% | 2.65% | 0.70% | -9.29% | -0.06% | 197.92% | 112.23% |
| BNP Paribas Easy BLUE | 463.10M Mid-cap | -2.20% | -0.89% | 0.52% | -5.19% | -5.19% | -2.63% | 1.50% | 49.76% |
| Inventiva S.A IVA | 391.52M Mid-cap | 0.70% | 8.71% | -10.87% | 23.18% | 36.02% | 32.41% | -46.04% | -71.29% |
Ownership & Short Interest
Insider Ownership
7.13%
Institutional Ownership
48.29%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
670K
Average 90-Day Volume
526K
Dbv Technologies Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Dbv Technologies would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DBV's 52-week high and low?
- In the last 52 weeks, Dbv Technologies reached a high of €2.38 (on May 14, 2025) and a low of €0.51 (on November 21, 2024).
- What is the market cap and P/E ratio for DBV?
- Curious about Dbv Technologies's size and valuation? Its market capitalization stands at 233.40M. When it comes to valuation, the P/E ratio (trailing twelve months) is -1.48, and the forward P/E (looking ahead) is -2.37.
- Does DBV pay dividends? If so, what's the yield?
- As for dividends, Dbv Technologies isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dbv Technologies's main competitors or similar companies to consider before investing?
When looking at Dbv Technologies, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abivax SA
ABVX4.49B Healthcare Biotechnology 474.95% 572.59% Valneva SE
VLA546.93M Healthcare Biotechnology 11.58% -65.68% Medincell S.A
MEDCL524.62M Healthcare Biotechnology -0.06% 197.92% BNP Paribas Easy
BLUE463.10M Healthcare Biotechnology -2.63% 1.50% Inventiva S.A
IVA391.52M Healthcare Biotechnology 32.41% -46.04% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dbv Technologies S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Dbv Technologies's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -148.09%, the Debt to Equity ratio from the most recent quarter is 8.92, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for DBV?
- Looking at Dbv Technologies's growth, its revenue over the trailing twelve months (TTM) was €3M. Compared to the same quarter last year (YoY), quarterly revenue grew by 26.20%, and quarterly earnings saw a YoY growth of N/A.
- How much of DBV stock is held by insiders and institutions?
- Wondering who owns Dbv Technologies stock? Company insiders (like executives and directors) hold about 7.13% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 48.29%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.